ClinicalTrials.gg
Active, not recruitingNCT06587074Updated Sep 19, 2024

Features of the Clinical Course and Prognosis in Patients With Idiopathic Pulmonary Hypertension When Using Modern Strategies of Specific Therapy

An observational study in Idiopathic Pulmonary Arterial Hypertension, sponsored by Russian Cardiology Research and Production Center. Active, not recruiting at 1 site in Russian Federation. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Russian Cardiology Research and Production Center · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
150
Ages
18 Years and older
Sex
All
01

Study summary

This study will be performed based on a retrospective analysis of the cases of 150-170 patients with IPAH observed at the Research Institute of Clinical Cardiology over the past 10 years, for a comparative assessment of the survival of groups of patients with IPAH diagnosed in the period 2004-2013 and 2014-2023.

The demographic, clinical, functional, hemodynamic characteristics of patients, comorbidity, blood biomarker levels, received PAH-specific and symptomatic therapy will be assessed in order to determine the clinical characteristics of patients with IPAH.

The prospective part of study will include 50 patients with IPAH.

02

Conditions studied

  • Idiopathic Pulmonary Arterial Hypertension
03

In context

Lead sponsor

Russian Cardiology Research and Production Center is the lead sponsor of 9 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

IPAH diagnosed patients in 2004-2023

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age over 18 years;
  • verified diagnosis of IPAH

Exclusion criteria

Exclusion Criteria:

  • age under 18 years;
  • Other etiology op PAH,
  • ischemic heart disease confirmed by MSCT of the coronary arteries or coronary angiography;
  • diseases of the musculoskeletal system that prevent 6MWT
  • severe liver dysfunction (more than 9 points on the scale, class C)
  • severe renal dysfunction (CC less than 15 ml/min), need for hemodialysis
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
150 participants (actual)
Target follow-up
3 Years
Patient registry
Yes

Groups and cohorts

  • Group 1
  • Group 2
06

What researchers measure

Primary outcomes

  1. Mortality in 3 years after diagnosed IPAH

    Time frame: 3 years

07

Study locations

1 site
  • Russian National Cardilogy Reasearch Center
    Moscow, 121552, Russian Federation
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2023 to primary completion in Aug 2024, 14 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2024
First posted
Sep 19, 2024
StartActual
May 30, 2023
Primary completionActual
Aug 14, 2024
CompletionEst.
Jul 22, 2025
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06587074
Lead sponsor
Russian Cardiology Research and Production Center
Responsible party
Tamila V. Martynyuk, MD, PhD (Professor, Head of pulmonary hypertension department, Russian Cardiology Research and Production Center) — Principal investigator
First posted
Sep 19, 2024
Start date
May 30, 2023
Primary completion
Aug 14, 2024
Completion
Jul 22, 2025 (estimated)
Last update
Sep 19, 2024

Study contacts

Tamila V Martyunuk, Yes
principal investigator · Russian National Cardiology Research Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion